Soft tissue sarcomas and central nervous system tumors in children with neurofibromatosis type 1

2011 ◽  
Vol 27 (11) ◽  
pp. 1885-1893 ◽  
Author(s):  
Emre Cecen ◽  
Dilek Ince ◽  
Kamer Mutafoglu Uysal ◽  
Erdener Ozer ◽  
Riza Cetingoz ◽  
...  
2019 ◽  
Vol 3 (3) ◽  
Author(s):  
Sara J Schonfeld ◽  
Diana M Merino ◽  
Rochelle E Curtis ◽  
Amy Berrington de González ◽  
Megan M Herr ◽  
...  

Abstract Excess sarcoma risks after childhood cancer are well established, but risks among young adulthood cancer survivors are poorly understood. Using US population-based cancer registry data, we compared bone and soft-tissue sarcoma risk vs the general population among 186 351 individuals who were diagnosed with nonsarcoma first primary malignancies at ages 20–39 years from 1975 to 2014 (follow-up through 2015) and survived at least 1 year. Bone sarcomas were rare (n = 50), but risk was statistically significantly elevated overall (2.9-fold) and greater than fivefold after Hodgkin lymphoma, non-Hodgkin lymphoma, and central nervous system tumors. Soft-tissue sarcomas were more common (n = 284) and risks were statistically significantly elevated approximately twofold overall and after melanoma and carcinomas of the breast, thyroid, and testis, and greater than fourfold after Hodgkin lymphoma and central nervous system tumors. Risks varied markedly by subtype, with the highest risks (greater than fourfold) for osteosarcoma and the soft-tissue subtypes of rhabdomyosarcoma and blood vessel and nerve sheath sarcomas. These data demonstrate elevated risk for sarcoma after a range of young adulthood cancers.


Cancers ◽  
2020 ◽  
Vol 12 (1) ◽  
pp. 114 ◽  
Author(s):  
Lobbous ◽  
Bernstock ◽  
Coffee ◽  
Friedman ◽  
Metrock ◽  
...  

Neurofibromatosis type 1 (NF1) is an autosomal dominant tumor predisposition syndrome that affects children and adults. Individuals with NF1 are at high risk for central nervous system neoplasms including gliomas. The purpose of this review is to discuss the spectrum of intracranial gliomas arising in individuals with NF1 with a focus on recent preclinical and clinical data. In this review, possible mechanisms of gliomagenesis are discussed, including the contribution of different signaling pathways and tumor microenvironment. Furthermore, we discuss the recent notable advances in the developing therapeutic landscape for NF1-associated gliomas including clinical trials and collaborative efforts.


1991 ◽  
Vol 21 (6) ◽  
pp. 389-394 ◽  
Author(s):  
F. Menor ◽  
L. Martí-Bonmatí ◽  
F. Mulas ◽  
H. Cortina ◽  
R. Olagüe

2015 ◽  
Vol 8 (1) ◽  
pp. 55-58
Author(s):  
Nedim Ongun ◽  
Eylem Değirmenci ◽  
Çağdaş Erdoğan ◽  
Attila Oğuzhanoğlu

2009 ◽  
Vol 26 (5) ◽  
pp. 663-667 ◽  
Author(s):  
Amy Rosenfeld ◽  
Robert Listernick ◽  
Joel Charrow ◽  
Stewart Goldman

Sign in / Sign up

Export Citation Format

Share Document